Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCRX Biocryst Pharmaceuticals

Closed 12-11 16:00:00 EST

7.58

-0.08

-1.04%

盘后7.64

+0.06+0.79%

19:58 EST

High7.77	Low7.54	Vol2.66M
Open7.68	D1 Closing7.66	Amplitude3.00%
Mkt Cap1.60B	Tradable Cap1.57B	Total Shares210.54M
T/O20.24M	T/O Rate1.28%	Tradable Shares207.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"Biocryst Pharmaceuticals","latestPrice":7.58,"timestamp":1765486800000,"preClose":7.66,"halted":0,"volume":2657266,"hourTrading":{"tag":"盘后","latestPrice":7.64,"preClose":7.58,"latestTime":"19:58 EST","volume":80089,"amount":607514.2884,"timestamp":1765501123866},"delay":0,"floatShares":207688912,"shares":210543224,"eps":-0.045319,"marketStatus":"Closed","change":-0.08,"latestTime":"12-11 16:00:00 EST","open":7.68,"high":7.77,"low":7.54,"amount":20240598.1371224,"amplitude":0.030026,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.045319,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":7.66,"preHourTrading":{"tag":"盘前","latestPrice":7.67,"preClose":7.66,"latestTime":"09:03 EST","volume":3184,"amount":24531.092976,"timestamp":1765461800485},"postHourTrading":{"tag":"盘后","latestPrice":7.64,"preClose":7.58,"latestTime":"19:58 EST","volume":80089,"amount":607514.2884,"timestamp":1765501123866},"volumeRatio":0.674524,"impliedVol":0.6445,"impliedVolPercentile":0.844},"requestUrl":"/m/hq/s/BCRX/wiki","defaultTab":"wiki","newsList":[{"id":"2590414513","title":"BioCryst Pharmaceuticals Inc - on Dec 9, Vincent J. Milano Elected as Next Chair of Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590414513","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590414513?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:28","pubTimestamp":1765456124,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCRX","BK4139","BK4547"],"gpt_icon":0},{"id":"2590513416","title":"Vincent J. Milano Named Next Chair of BioCryst Pharmaceuticals Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513416","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513416?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:26","pubTimestamp":1765455990,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. announced that Nancy J. Hutson, Ph.D. will retire from the Board of Directors, effective either upon the closing of the proposed acquisition of Astria Therapeutics, Inc. or at the company's 2026 annual meeting of stockholders, whichever comes first. Vincent J. Milano has been elected as the next Chair of the Board, to assume the role upon Dr. Hutson's retirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7r4N4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","ATXS","BK4139","BCRX"],"gpt_icon":0},{"id":"2588288968","title":"BioCryst Grants New Hires Stock Options and RSUs as Inducement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588288968","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588288968?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849625,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. has granted stock options to purchase a total of 57,100 shares and restricted stock units  covering 46,400 shares of common stock to four newly hired employees. The stock options have an exercise price of $7.13 per share, equal to the closing price on the grant date of December 1, 2025. Both the options and RSUs will vest in four equal annual installments starting on the first anniversary of the grant date, provided the employees remain with the company. Each stock option carries a 10-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 04, 2025, and is solely responsible for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL24SY75:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4547","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","BK4588","NDAQ","LU0314104364.USD","BK4139","BCRX","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2588200710","title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588200710","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588200710?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:41","pubTimestamp":1764805283,"startTime":"0","endTime":"0","summary":"Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL1kBtHd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2588367049","title":"BRIEF-Biocryst Receives Early Termination Of Hart-Scott-Rodino Waiting Period For Astria Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588367049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588367049?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:05","pubTimestamp":1764767146,"startTime":"0","endTime":"0","summary":"BRIEF-Biocryst Receives Early Termination Of Hart-Scott-Rodino Waiting Period For Astria AcquisitionDec 3 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:BIOCRYST RECEIVES EARLY TERMINATION OF HART-SC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA6BK0ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2588046804","title":"BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046804","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046804?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:42","pubTimestamp":1764765750,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals  said Wednesday it received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to the company's proposed acquisition of Astria Therapeutics.The termination satisfied one of the conditions for the deal's completion, expected in Q1, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2588043423","title":"BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043423?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:00","pubTimestamp":1764763213,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals disclosed plans to merge with Astria Therapeutics. The announcement highlights expectations regarding the timing of the closing and potential benefits, including anticipated synergies from the combined operations. However, BioCryst noted there are risks and uncertainties that could affect the completion and outcome of the merger. The companies also referenced the possibility of integration challenges, potential expenses, and impacts on business relationships as factors that could influence the transaction. Further details are available in filings with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNew","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLVYpBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","BK4139","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","ATXS","BK4547","IE00B64PRP62.GBP","BCRX"],"gpt_icon":0},{"id":"2588043217","title":"BioCryst Pharmaceuticals Inc - Expects Merger to Close in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043217?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:00","pubTimestamp":1764763201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA6BK0ZH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2588525530","title":"How New Pediatric APeX-P Data at BioCryst (BCRX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2588525530","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588525530?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:14","pubTimestamp":1764684852,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals recently announced new one-year data from its APeX-P trial, highlighting that ORLADEYO (berotralstat) treatment led to early and sustained reductions in hereditary angioedema (HAE) attack rates in children aged 2 to under 12 years.\nThe results also underscored the significant psychosocial impact of HAE on pediatric patients and their caregivers, further supporting the importance of effective therapies for this population.\nWe'll explore how these clinical findings in...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-pediatric-apex-p-data-at-biocryst-bcrx-has-changed-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-pediatric-apex-p-data-at-biocryst-bcrx-has-changed-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4547","HAE","LU1169589451.USD","BCRX","IE0034390439.USD","IE00BLDYK493.USD","BK4139","LU0106261612.USD","IE00B64QTZ34.USD","IE00B19Z6F94.USD","LU0012050646.USD","LU0205194284.USD","LU1169590202.USD","BK4198","LU0205193047.USD"],"gpt_icon":0},{"id":"2584942457","title":"BioCryst (BCRX) Receives a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2584942457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584942457?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:55","pubTimestamp":1763560558,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00. Chico covers the Healthcar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biocryst-bcrx-receives-a-buy-from-wedbush-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biocryst-bcrx-receives-a-buy-from-wedbush-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2584705961","title":"Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Promising Pediatric ORLADEYO Trial Results and FDA Review Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2584705961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584705961?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:27","pubTimestamp":1763494032,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) released fresh data from its APeX-P trial, showing that children aged 2 to 12 treated with ORLADEYO experienced early and lasting reductions in their monthly hereditary angioedema attack rates.\nSee our latest analysis for BioCryst Pharmaceuticals.\nBioCryst Pharmaceuticals has attracted attention following its promising new pediatric trial data and the ongoing FDA review of ORLADEYO's oral granule formulation. After a volatile year, momentum looks to be...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-prom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-prom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2584467177","title":"BioCryst Director Machelle Sanders Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584467177","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584467177?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:07","pubTimestamp":1763413663,"startTime":"0","endTime":"0","summary":"Machelle Sanders, Director of BioCryst Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLb8jpVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst Director Machelle Sanders Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2583653837","title":"Did BioCryst's (BCRX) ORLADEYO Revenue Guidance and Pediatric Data Just Shift Its Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583653837","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583653837?lang=en_us&edition=fundamental","pubTime":"2025-11-15 19:20","pubTimestamp":1763205656,"startTime":"0","endTime":"0","summary":"Earlier this month, BioCryst Pharmaceuticals reported third quarter revenue of US$159.4 million and net income of US$12.9 million, alongside raising its full year 2025 global net ORLADEYO revenue guidance and projecting a profitable year.\nThis marks a turnaround from prior losses and highlights the impact of growing ORLADEYO adoption, with analyst attention on the company’s new pediatric HAE data as a potential market expansion lever.\nWe’ll explore how BioCryst’s raised revenue outlook and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/did-biocrysts-bcrx-orladeyo-revenue-guidance-and-pediatric-d","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/did-biocrysts-bcrx-orladeyo-revenue-guidance-and-pediatric-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BCRX"],"gpt_icon":0},{"id":"2582037977","title":"BioCryst to Acquire Astria Therapeutics for $8.55 Per Share and Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2582037977","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582037977?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:02","pubTimestamp":1762952555,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals, Inc. and Astria Therapeutics, Inc. have entered into a definitive agreement under which BioCryst will acquire all outstanding shares of Astria. The consideration for each Astria share will consist of $8.55 in cash and 0.59 shares of BioCryst common stock. The transaction has received unanimous approval from the boards of both companies and is expected to close in the first quarter of 2026, subject to customary closing conditions and Astria stockholder approval. Upon completion, Astria CEO Jill C. Milne will join the BioCryst Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLc1NDq5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATXS","BK4547","BCRX"],"gpt_icon":0},{"id":"2581093327","title":"BioCryst Unveils Data Showing ORLADEYO Cuts HAE Attacks in Children in Yearlong Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093327","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093327?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434019,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. has announced new data from the ongoing APeX-P clinical trial evaluating ORLADEYO  in pediatric patients with hereditary angioedema  aged 2 to under 12 years. The results, presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology  in November 2025, show early and sustained reductions in monthly HAE attack rates over one year of treatment with once-daily ORLADEYO oral granules. The company also highlighted findings on the negative psychosocial impact of HAE and emergency care visits on children and their caregivers. A New Drug Application for ORLADEYO oral granules as prophylaxis in this pediatric population is currently under review by the U.S. Food and Drug Administration, with a decision expected by the end of 2025. If approved, ORLADEYO would be the first targeted oral prophylactic therapy for HAE patients aged 2 to under 12 years.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6Sp6xw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4139","BK4112","NDAQ","BCRX","LU0314104364.USD","BK4547","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581093826","title":"BioCryst Presents New Data at Acaai Highlighting Burden of Hae on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated With One Year of Orladeyo® (Berotralstat)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093826?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA8D6HYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"1179627829","title":"Stock Track | BioCryst Pharmaceuticals Soars 5.03% Pre-Market on Conference Presentation and Positive Analyst Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1179627829","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179627829?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:29","pubTimestamp":1762356592,"startTime":"0","endTime":"0","summary":"Shares of BioCryst Pharmaceuticals (BCRX) are soaring 5.03% in pre-market trading on Wednesday, as investors react to a series of positive developments for the company. The surge comes amid news of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCRX"],"gpt_icon":0},{"id":"1109520934","title":"Stock Track | BioCryst Pharmaceuticals Plummets 5.03% as Analysts Cut Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1109520934","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109520934?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:36","pubTimestamp":1762270584,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) saw its stock price plummet 5.03% in Tuesday's pre-market trading session, following downgrades from multiple analysts. The sharp decline comes as Wall Street firms...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCRX"],"gpt_icon":0},{"id":"2580782358","title":"BioCryst Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2580782358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580782358?lang=en_us&edition=fundamental","pubTime":"2025-11-04 18:52","pubTimestamp":1762253520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 05:52 ET (10:52 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2580207716","title":"Barclays Sticks to Their Hold Rating for BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580207716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580207716?lang=en_us&edition=fundamental","pubTime":"2025-11-04 15:57","pubTimestamp":1762243066,"startTime":"0","endTime":"0","summary":"In a report released today, Gena Wang from Barclays maintained a Hold rating on BioCryst, with a price target of $9.00. The company’s shares closed...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-biocryst-bcrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-biocryst-bcrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":-0.0242},{"period":"1month","weight":0.0639},{"period":"3month","weight":-0.0508},{"period":"6month","weight":-0.2613},{"period":"1year","weight":-0.034},{"period":"ytd","weight":0.0186}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.580645,"avgChangeRate":0.031172},{"month":2,"riseRate":0.516129,"avgChangeRate":-0.010813},{"month":3,"riseRate":0.354839,"avgChangeRate":0.014971},{"month":4,"riseRate":0.5625,"avgChangeRate":0.048894},{"month":5,"riseRate":0.5625,"avgChangeRate":0.062945},{"month":6,"riseRate":0.59375,"avgChangeRate":0.027194},{"month":7,"riseRate":0.5625,"avgChangeRate":0.113207},{"month":8,"riseRate":0.59375,"avgChangeRate":0.099672},{"month":9,"riseRate":0.34375,"avgChangeRate":-0.049493},{"month":10,"riseRate":0.5,"avgChangeRate":-0.046955},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.004089}],"exchange":"NASDAQ","name":"Biocryst Pharmaceuticals","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biocryst Pharmaceuticals,BCRX,Biocryst Pharmaceuticals股票,Biocryst Pharmaceuticals股票老虎,Biocryst Pharmaceuticals股票老虎国际,Biocryst Pharmaceuticals行情,Biocryst Pharmaceuticals股票行情,Biocryst Pharmaceuticals股价,Biocryst Pharmaceuticals股市,Biocryst Pharmaceuticals股票价格,Biocryst Pharmaceuticals股票交易,Biocryst Pharmaceuticals股票购买,Biocryst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}